Site icon Duncan Bucknell

Pharma & Biotech Global Week in Review 12 Aug 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page:

Highlights this week included:

Yasmin (Drospirenone) – US: CAFC affirms invalidity of Yasmin patent on the grounds of obviousness: Bayer Schering v Barr Labs (Orange Book Blog) (Patent Baristas) (Patent Docs) (SmartBrief)

India warns on generic drugs seizure (GenericsWeb) (PatentBIOtech)


Alnylam to donate RNAi patents to patent pool (Patent Docs)

Pay-for-delay: The Economist roars (IPKat)

PCT v 2.0 on the anvil? – Reports that WIPO intends to impose ‘Global Patenting Regime’ on developing world (Spicy IP)

Members of Human Rights Expert Committee at UN question patents on food (Intellectual Property Watch)

The impact of the global financial crisis on biotechnology development (BiotechBlog)

Australia: Patent cures, not genes, cancer patients argue: easier said than done – Senate inquiry into gene patenting (IP Osgoode)

Canada: RCMP shuts down counterfeit drug ring (Michael Geist)

Canada: Federal Court ruling upholds data protection period for research-based innovative drug companies: Canadian Generic Pharmaceutical Association v Minister of Health and Attorney General of Canada (IP Osgoode)

India warns on generic drugs seizure (GenericsWeb) (PatentBIOtech)

India: A critical analysis of the Indian policy on seeds – bane or boon? (Spicy IP)

India: Rigging data: IPRs and the impact of counterfeits (Spicy IP)

India: A desi model for affordable healthcare? (Spicy IP)

UK: Hindsight going forward: taking the risk factor into account: Lilly Icos, Pfizer Enterprises, Merck, AstraZeneca & Ors v 8pm Chemists & Ors (IP finance)

US: Gene patenting debate continues – round two (Patent Docs)

US: Follow-on biologics news briefs – no 7 (Patent Docs)

US: BIO urges Supreme Court to reject rigid Bilski rule (PatentBIOtech)

US: Cargill withdraws patent infringement case before ITC against Nantong Foreign Medicines & Health Products Co Ltd regarding importation and sale of non-shellfish derived glucosamine (S&F)

US: Antitrust attack on reverse payment settlements in pharma patent cases (IP ADR Blog)


Antara (Fenofibrate) – US: Paddock seeks declaratory judgment of non-infringement of Oscient’s Antara patent based on its ANDA to manufacture a generic version of the drug (Patent Docs)

Benicar (Olmesartan) – US: Daiichi prevails in Benicar infringement suit against Mylan (Patent Docs)

Cipralex (Citalopram) – Israel: Lundbeck loses appeal for patent term extension for Cipralex in Jerusalem District Court, requests leave to appeal to Supreme Court (The IP Factor)

Clarinex (Desloratadine) – US: Schering-Plough settles patent dispute with Orchid Chemicals & Pharmaceuticals and Orgenus Pharm over their manufacture of generic Clarinex (SmartBrief)

Elestat (Epinastine) – US: Sandoz seeks declaratory judgment of invalidity, unenforceability and non-infringement of Allergan’s patent based on its filing of an ANDA to manufacture generic Elestat (Patent Docs)

Hectorol (Doxercalciferol) – US: Genzyme files patent infringement suit in response to Roxanes filing of an ANDA to manufacture generic Hectorol (Patent Docs)

Pantozol (Pantoprazol) – Netherlands: Nycomed fails in bid to protect shape, colour and dosage imprint on pills as a trade mark in dispute with Sandoz (Class 46)

Restoril (Temazepam) – US: District Court New Jersey denies Covidien’s motion to enjoin URL Pharma from manufacturing or marketing generic Restoril (Patent Docs)

Yasmin (Drospirenone) – US: CAFC affirms invalidity of Yasmin patent on the grounds of obviousness: Bayer Schering v Barr Labs (Orange Book Blog) (Patent Baristas) (Patent Docs) (SmartBrief)

Zetia (Ezetimibe) – US: District Court New Jersey to hear Glenmark’s patent challenge against Schering Plough’s Zetia on 19 August (GenericsWeb)


Exit mobile version